Laurus Labs Limited, together with its subsidiaries, engages in the research, development, manufacture, and sale of medicines and active pharmaceutical ingredients (APIs) in India and internationally. It operates through Generics APIs, Generics Finished Dosage Forms (FDF), and Synthesis segments. The Generics APIs segment develops, manufactures, and sells APIs and advanced intermediates for anti-retroviral (ARV), oncology, hepatitis C, cardiovascular, antidiabetic, anti-asthmatic, gastroenterology, and ophthalmic therapeutic areas. The Generics FDF segment develops and manufactures oral solid formulations for ARVs, anti-diabetic, cardiovascular, proton pump inhibitors, and central nervous system. The Synthesis segment provides contract development and manufacturing services for pharmaceutical companies. The company also manufactures and sells specialty ingredients used in the nutraceutical, dietary supplements, and cosmeceutical products. In addition, it offers chemistry, IP development, business support, and related services to the pharmaceutical community. The company was incorporated in 2005 and is based in Hyderabad, India. The ISIN of this stock is INE947Q01028.